LAX.SH
VINEET LABORATORIES LTD·Healthcare Companies·Pharmaceuticals & Biotechnology Companies
Price
37.19
-2.19%52W Range
Market Cap
₹71.43 Cr
Traded: ₹0.22 Cr (0.30%) 0.0x
Free Float: ₹45.27 Cr (0.48% of FF traded)
Volume · 60D trend
56.95 K 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
RS Score
Create a free account to unlock your edge
Scanners, market pulse, FII/DII data, and TradingView charts — free forever
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
48 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Sales | -- | -- | -27.0% | -- | -44.0% | Decelerating |
| ROE | -- | -9.0% | -22.0% | -- | -- | Decelerating |
| Return | -- | -- | -6.0% | +37.0% | -- | Accelerating |
| Profit | -- | -- | -- | -- | -31.0% | -- |
Quarterly Results
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023PDF ↗ | Dec 2022PDF ↗ | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 16 | 17 | 7 | 14 | 18 | 19 | 24 | 37 | 33 | 43 | 38 | 57 | 67 |
| Expenses | 13 | 14 | 7 | 25 | 22 | 19 | 25 | 34 | 33 | 39 | 37 | 51 | 65 |
| Operating Profit | 2 | 3 | 0 | -11 | -4 | -0 | -1 | 3 | -1 | 4 | 0 | 6 | 2 |
| Other Income | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 0 | 1 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit Before Tax | 1 | 0 | -1 | -11 | -6 | -2 | -2 | 1 | -2 | 3 | -1 | 5 | 0 |
| Tax % | -3.7% | -8.1% | -4.4% | -6.2% | 0.5% | 7.0% | -1.8% | -34.0% | -11.1% | 4.7% | -2.3% | 26.8% | -239.0% |
| Net Profit | 1 | 0 | -1 | -11 | -6 | -2 | -2 | 2 | -2 | 2 | -1 | 4 | 1 |
| Exceptional Items | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| EPS (Rs) | 0.4 | 0.2 | -0.5 | -5.5 | -3.0 | -0.9 | -1.1 | 1.0 | -1.1 | 1.3 | -0.7 | 1.9 | 0.7 |
| Sales Growth (YoY) | -13.5% | -8.1% | -68.8% | -62.0% | -44.6% | -56.3% | -36.4% | -35.2% | -51.1% | -- | -- | -- | -- |
| Sales Growth (QoQ) | -10.2% | 134.1% | -47.2% | -22.2% | -4.5% | -20.5% | -35.6% | 13.5% | -24.7% | 15.6% | -34.4% | -14.3% | -- |
| OP Growth (YoY) | 160.0% | 1125.8% | 139.2% | -422.8% | -545.3% | -107.4% | -403.8% | -41.1% | -132.8% | -- | -- | -- | -- |
| OP Growth (QoQ) | -22.0% | 925.8% | 102.8% | -167.3% | -1232.3% | 60.8% | -123.1% | 634.4% | -115.3% | 1503.8% | -95.5% | 197.9% | -- |
| Profit Growth (YoY) | 115.0% | 122.0% | 59.0% | -648.0% | -176.0% | -176.0% | -70.0% | -46.0% | -249.0% | 151.0% | -224.0% | 8.0% | 2.0% |
| EPS Growth (YoY) | 114.8% | 122.1% | 59.5% | -648.0% | -175.0% | -175.4% | -70.8% | -46.0% | -250.0% | -- | -- | -- | -- |
| EPS Growth (QoQ) | 109.5% | 146.7% | 91.8% | -84.5% | -212.6% | 14.4% | -211.0% | 192.6% | -185.7% | 293.9% | -135.1% | 156.9% | -- |
| OP Margin | 15.8% | 18.3% | 4.2% | -78.4% | -22.8% | -1.6% | -3.3% | 9.2% | -2.0% | 9.6% | 0.7% | 10.2% | 2.9% |
| Net Margin | 5.4% | 2.3% | -11.7% | -74.8% | -31.6% | -9.7% | -8.9% | 5.2% | -6.3% | 5.6% | -3.3% | 6.2% | 2.1% |
| Material Cost % | 62.0% | 68.0% | 62.0% | 146.0% | 95.0% | 71.0% | 79.0% | 71.0% | 81.0% | 70.0% | 82.0% | 71.0% | 89.0% |
| Employee Cost % | 7.0% | 5.0% | 14.0% | 10.0% | 7.0% | 7.0% | 6.0% | 5.0% | 5.0% | 3.0% | 4.0% | 3.0% | 3.0% |
| P/S | 1.31 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 5.10 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Vineet Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/10/2026 ,inter alia, to consider and approve the unaudited Standalone ....
Compliance certificate under Reg. 74(5) od SEBI (DP) Regulations 2018
We are hereby submitting the exchange regarding the appointment of Avula Navaneeswara Reddy as Non Executive Non Independent Director of the company with effect from 14th October 2026
We wish you to inform you that Mr. Vennapusa Premanand Reddy (DIN:02512956) has ceased to be a director of Vineet Laboratories with effect from October 14, 2026.
We are hereby clarify that due to clerical oversight, an amount of Rs. 21.29 Lakhs was erroneously reflected under Income taxes paid in the cash flow statement for the year ended 31st march 2026.
Resignation of Statutory Auditor
The Trading window for dealing in the securities of the Company will remain closed form 01st October, 2026 till 48 hours after the announcement of Standalone Un-audited Financial Results ....
We wish you to inform you that Rigistrar of Companies, Hyderabad has granted an extension of two months for holding the 10th Annual General Meeting of the company in respect of financial ....
Updated Financial Results for the Quarter and Finacial year ended 31st March 2026
The Board of Directors of the company in its meeting held today i.e., on August 25, 2026 has: Approved the Audited Standalone Financial Results of the Company for the fourth quarter and ....
The Board of Director of the company in its meeting held on August 25 2026 Approved the Audited Standalone Financial Results for the fourth quarter and the financial year ended on 31st ....
Vineet Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/08/2026 ,inter alia, to consider and approve the Audited Standalone ....
Please find the attached Monitoring Agency Report issued by CRISIL rating Limited for quarter ended June 30, 2026
We are hereby informed that Mr. Gaddam Venkata Ramana ( DIN:00031873) has ceased to hold office of Managing Director of Vineet Laboratories with effect form July 21 2026. It further clarified ....
Appointment of Rajesh Kumar Kathulla as an Additional Director (Executive Catagory) of the company with effect from 11th day of June, 2026
Intimation regarding diferment of Board Meeting
Vineet Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 15/07/2026 ,inter alia, to consider and approve Audited Standalone Financial Results
Outcome of Board Meeting Held on May 30,2026 Deferment of Consideration of Audited Standalone Financial Results
We are hereby submitting the resignation of Company Secretary.
Vineet Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 ,inter alia, to consider and approve the Audited Standalone ....
Please find the attached Monitoring Agency Report issued by Crisil Rating Limited for the quarter ended March 31, 2026
We are hereby submitting the certificate issued by Venture Capital and Corporate Investments Private Limited in compliance with Regulation 74(5) of SEBI (Depositories and Participants) ....
The Trading window for dealing in securities of the Company will remain closed from 01st April, 2026 till 48 hours after announcement of Standalone Audited Financial results for the Fourth ....
We enclose herewith the copies of Un-audited standalone financial results of the company for the Third quarter and Nine months ended on December 31, 2025 published in following Newspapers ....
The Board of Directors in its meeting held today i.e on February 14, 2026 has considered and approved the Unaudited Standalone Financial Results along with the Limited Review Report submitted ....
The Board of Directors of the company in its meeting held today i.e., Saturday, February 14, 2026 has: considered and approved the unaudited standalone financial results of the company ....
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Arjun Aggarwal
Vineet Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2026 ,inter alia, to consider and approve unaudited standalone financial ....
We are hereby submitting the Voting results of Extra-Ordinary General Meeting of Vineet Laboratories Limited held on Saturday, February 07, 2026.
We are hereby submitting the proceedings of EGM of Vineet Laboratories Limited held on Saturday, February 07, 2026 through Video Conferencing (VC) / Other Audio-Visual Means (OAVM).
We are hereby submitting the trading approvals received from BSE and NSE vide their letters dated February 04, 2026 for the Equity shares allotted under Rights Issue of the Company.
We are submitting copies of advertisements published by the Company today i.e. February 02, 2026, in respect of matters relating to Basis of Allotment of Rights Issue of Equity Shares of ....
We would like to inform that the Rights Issue Committee of the Board of Directors of Vineet Laboratories Limited ("the Company") has today i.e. February 02, 2026, considered and approved ....
We are hereby submitting the copies of the Addendum to the Letter of Offer dated December 17, 2025 published today in the following newspapers: 1. Financial Express (English National Daily ....
We are hereby submitting the Newspaper publication made in Financial Express and Nava Telangana regarding the notice of Extra-Ordinary General Meeting of the Company to be held on February 07, 2026
The Rights Issue Committee of the Board of Directors in its meeting held on January 13, 2026, has decided to extend the "Last date for On Market Renunciation" and the "Issue Closing date" ....
The Extra-Ordinary General Meeting of the Company is being conducted on Saturday, February 07, 2026 at 11.00 A.M. We are hereby submitting the notice of the EGM.
We are hereby submitting the certificate issued by Venture Capital and Corporate Investments Private Limited in compliance with Regulation 74(5) of the SEBI (Depositories and Participants) ....
The Board of Directors of the company in its meeting held today i.e., on Wednesday, January 07, 2026 has approved: 1. Notice of Extra - Ordinary General Meeting to obtain the approval ....
We are hereby submitting the Newspaper Advertisements published before the date of opening of the Rights Issue as required under Regulation 84(1) of SEBI (ICDR) Regulations, 2018.
The Trading Window for dealing in the securities of the Company will remain closed from 01st January, 2026 till 48 hours after the announcement of Standalone Un-audited Financial results ....
The Company is hereby submitting the Letter of Offer for Rights Issue.
The Company has made necessary arrangements with NSDL and CDSL for credit of Rights Entitlements in dematerialized form in the demat accounts of the Eligible Equity Shareholders.
We hereby inform that the Rights Issue Committee of the Board in its meeting held today, i.e., December 17, 2025 has inter alia considered and approved the Rights Issue Price, Rights Issue ....
We hereby inform that the Rights Issue Committee in its meeting held today, December 17, 2025 has approved the Record Date for the proposed Rights Issue to be Tuesday, December 23, 2025.
We hereby inform that the Rights Issue Committee of the Board in its meeting held today i.e. on December 17, 2025 has inter alia considered and approved the Rights Issue Price, Entitlement ....
The Company has received the In-Principle approval(s) from National Stock Exchange of India Limited on December 02, 2025 and BSE Limited on December 16, 2025 for undertaking Rights Issue ....
In continuation to our communication dated December 15, 2025, regarding convening of meeting of Rights Issue Committee on December 16, 2025, we inform you that the meeting, which was commenced ....
In continuation to our communication dated December 12, 2025, regarding the convening of meeting of Rights Issue Committee on December 15, 2025, we inform you that the meeting, which was ....
In continuation to our communication dated December 11, 2025, regarding the convening of the meeting of the Rights Issue Committee on December 12, 2025, we inform you that the meeting, ....